Senolytics in idiopathic pulmonary fibrosis: first-in-human, open-label pilot (Justice et al., 2019)
Human open-label pilot (feasibility / biomarker)
Record verify: verified against primary source
| Design | First-in-human open-label pilot |
| N | 14 |
| Registry | NCT02874989 |
| PMID | 30616998 |
| DOI | 10.1016/j.ebiom.2018.12.052 |
| Citation status | pmid+doi verified via PubMed eutils (EBioMedicine 2019;40:554-563; PMC6412088); NCT02874989 from websearch |
Identifiers: DOI verified; PMC verified; PMID verified; trial registry id verified. Record-level verification and identifier-level status are separate: a record can be fully verified against its primary publication while an identifier that cannot apply to the study type — a trial registry ID for an animal study, for instance — is marked not applicable. No identifier is fabricated, and none is left in a “pending” state.
Not the same study
This record is the 2019 first-in-human open-label pilot (Justice et al., EBioMedicine 2019;40:554-563; PMID 30616998), which had no control group. A separate, later publication reports a single-blind randomized placebo-controlled pilot in the same indication (Nambiar et al., EBioMedicine 2023;90:104481; PMID 36857968, n=12). The two share the registry identifier NCT02874989, so the registry number alone does not distinguish them. They must not be merged: the physical-function improvement reported here was uncontrolled, and the later controlled pilot did not find a meaningful difference between the treatment and placebo groups.
Five-qualifier claim
| Species / population | Adults with idiopathic pulmonary fibrosis (n=14), two-centre open-label pilot. |
| Exposure, route, schedule | Oral dasatinib 100 mg/day + quercetin 1250 mg/day, 3 days/week over 3 weeks (intermittent). |
| Comparator / duration | Single-arm, open-label; no control group and no blinding. Approximately 3-week intermittent intervention with short follow-up. |
| Endpoint / numeric result | Primary endpoints were feasibility (retention/completion); most consistent secondary improvement was in physical function/mobility measures (e.g. 6-minute walk, gait speed, chair-stands). |
| What it did NOT establish | Not powered for efficacy; no control group, so the observed physical-function improvement cannot be attributed to the drug. No lung-function disease-modification claim; no lifespan outcome. |